Christine Malmberg
Vice President, Market Access and Pricing
Expertise:
Christine is a former hospital-based clinician who has worked as a market access consultant to the Canadian pharma industry for over 15 years. She has substantial knowledge of the Canadian reimbursement environment, having gained extensive “hands-on” experience developing clinical and economic submission documents for CADTH, INESSS, private payers, provinces, and hospitals.
Ensuring dossiers are aligned with business strategy while effectively arguing unmet clinical need and place in therapy, Christine has worked on and/or led numerous successful drug submissions in all manner of therapeutic areas, including oncology and rare diseases.
As operations and clinical lead within Market Access and Pricing at EVERSANA, Christine supports project teams to ensure clients efficiently and successfully navigate the complex and rigorous Canadian HTA process. She is also passionate about mentoring newer market access professionals.
Christine is a licensed pharmacist in British Columbia with a bachelor of pharmacy degree from the University of British Columbia and a doctor of pharmacy degree from the University of Toronto.
Articles by Christine Malmberg
Canadian Market Access Success Starts With the Right Partner
The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target Zero, time-limited recommendations, streamlined economic reviews, rolling reviews). At the same time, Canadian drug prices continue to be regulated under PMPRB’s interim guidelines, the pCPA is increasingly leveraging the Targeted Negotiation Process, and the federal government has taken the first steps toward National Pharmacare. This rapidly changing environment brings both opportunities and potential threats for those seeking to commercialize innovative therapies in Canada. More than ever, market access success depends on having the right […]
Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment
These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes and key stakeholders, careful strategic planning, sound tactics and skilled execution. Some key steps and considerations to maximize the chances of timely reimbursement are as follows: Up to 18 months pre-NOC: Information-gathering and early strategy work Conduct a market access landscape assessment Identify unmet needs and potential place in therapy Perform a strategic review of the clinical evidence to identify gaps that may pose a risk during HTA review, and potential mitigation strategies Evaluate […]